Source BioScience reports strong Q3

Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations.

The company said the three months to the end of September had been a period of sustained growth and

development with increased revenue in both its LifeSciences and Healthcare divisions.

The performance was underpinned by growth in the firm's cytology business (which studies cell structure), driven by the adoption of automated imaging for cervical cancer screening.

The LifeSciences division also took increasing market share for DNA sequencing in the UK.

Source said it was in a robust financial position with £2m cash as of September 30th, up from £1.8m at the end of June.

MM